Dean Clift

Dean carried out his early postdoctoral research at the LMB in Cambridge, UK with Dr Melina Schuh where he invented Trim-Away technology, which utilizes off-the-shelf antibodies and the natural function of intracellular antibody receptor and E3 ubiquitin ligase TRIM21 to rapidly degrade endogenous cellular proteins. Dean then worked with Dr Leo James, LMB to elucidate the mechanism of TRIM21 activation, before moving to TRIMTECH to exploit this mechanism to develop new therapeutics that selectively degrade pathogenic protein aggregates.